Kalbe Farma Stock - Analyst views and long-term positioning

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 16:43 WIB. Details in the imprint.

Kalbe Farma (ID1000096605) is one of Indonesia’s best-known healthcare groups with a broad portfolio in prescription drugs, consumer health and nutrition. With no major ad-hoc news today, the focus shifts to how the company’s stock fits into Indonesia’s long-term healthcare and consumer trends.

Analyst coverage and estimates

Kalbe Farma’s investor relations site highlights its positioning as a leading Indonesian pharmaceutical and consumer health company, but detailed consensus earnings data are limited compared with large-cap global drug makers. The company’s English-language financial reports summarize revenue, margins and business segments for recent years. The IR section provides access to annual and quarterly reports.

Publicly available analyst snapshots from regional brokers typically focus on core themes such as Indonesia’s growing middle class, rising healthcare spending and the company’s ability to defend margins in prescription and over-the-counter products. Exact target prices and rating distributions vary by provider and are often behind paywalls, so retail investors frequently rely on summary data from local broker platforms.

Long-term growth drivers

Indonesia’s population exceeds 270 million, and healthcare spending has been rising over the past decade as insurance coverage and incomes increase. Domestic players like Kalbe Farma benefit from familiarity with local regulation, distribution networks and consumer preferences, which can support long-term volume growth even when pricing conditions are competitive.

In addition to pharmaceuticals, Kalbe is active in nutritionals, including products targeting children and adults, and in distribution services across the archipelago. This diversification gives the group multiple revenue streams linked to underlying demographics and lifestyle trends, from infant nutrition to chronic-disease treatments in an aging population.

How the company makes money

Kalbe Farma generates revenue across several business segments, typically including prescription pharmaceuticals, consumer health products, nutritionals and distribution/logistics services in Indonesia and selected export markets. Its product portfolio ranges from branded generics and over-the-counter medicines to milk-based nutrition formulas and medical devices.

Where the stock trades today

Kalbe Farma shares trade on the Indonesia Stock Exchange (IDX) in Jakarta under the ticker KLBF, denominated in Indonesian rupiah; the latest available quote shows the stock changing hands on the domestic market, reflecting local investor sentiment.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.